Whitehawk Therapeutics Inc
WHWK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | 0.09 | 0.06 | -0.00 |
| FCF Yield | -71.66% | -115.32% | -17.34% | -10.49% |
| EV / EBITDA | -0.89 | 0.09 | -4.28 | -1.78 |
| Quality | ||||
| ROIC | -126.06% | -67.57% | -37.81% | -77.90% |
| Gross Margin | -108.04% | -112.44% | -123.43% | -1,656.25% |
| Cash Conversion Ratio | 0.93 | 0.91 | 0.82 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.53% | 179.12% | 1.43% | 14.35% |
| Free Cash Flow Growth | 3.82% | -27.06% | -122.90% | -76.91% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 0.86 | 0.64 | 4.02 |
| Interest Coverage | -438.04 | -311.40 | -272.53 | -167.24 |
| Efficiency | ||||
| Inventory Turnover | 10.18 | 8.05 | 18.27 | 0.00 |
| Cash Conversion Cycle | 104.21 | 85.98 | 26.86 | -119.48 |